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Abstract
An increasing number of studies suggest that angiotensin (Ang) II contributes to the pathology of cerebrovascular disease
possibly through injuring of the brain microvascular endothelial cells (BMEC), but the mechanisms involved are not well elucidated.
Recent studies reveal the importance of Ang II in reactive oxygen species induction and endothelial injury. Hence, the present study
investigated the involvement of oxidative stress in Ang II-induced BMEC injury.
Our results showed that 10-6 mol/L Ang II increased lactate dehydrogenase (LDH) leakage and inhibited the viability of primary
cultured BMEC. Incubation with 10-6 mol/L of Ang II for 48 hr increased the extracellular and intracellular malondialdehyde (MDA)
content and decreased the activities of intracellular glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) significantly.
These effects were abolished by pretreatment with the selective AT1 receptor antagonist losartan, but not with the AT2 selective antagonist PD123319. Combining Losartan with PD123319 neither diminished nor promoted the effect of losartan alone. These findings
indicated that Ang II induced injury of BMEC may result from oxidative stress by activating AT1 receptors. This injury may in turn
lead to the development of cerebrovascular disease.
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Introduction
The endothelium of the cerebral blood microvessels,
which is the major component of the blood-brain
barrier (BBB), responds dynamically to the flowing
substances, free radical exposure and cytokine generation.
Microvascular endothelial dysfunction in the brain is
notably the cause of cerebral edema and ischemia injury(1).
Accumulating evidence suggest that angiotensin (Ang)
II, the main effector of the renin-angiotensin system (RAS),
participates in the initiation and regulation of processes
that occur during brain ischemia (2). Elevated levels of
Ang II have been documented during brain ischemic
injury(3). Maeda et al. reported that the area of the core
lesion after middle cerebral artery (MCA) occlusion was
significantly reduced in angiotensinogen-knockout mice(4).
Our laboratory previously proved that Ang II-injured brain
microvascular endothelial cells (BMEC) participate in the
development of cerebrovascular disease(5). However, the
underlying mechanism of Ang II-induced cerebrovascular
endothelial cell injury is not full understood.
Oxygen free radicals (OFR) are increasingly implicated
as key mediators of cerebral injury. Antioxidant defenses
such as free radical scavengers and antioxidant enzymes
including superoxide dismutase (SOD), catalase, and
glutathione peroxidase (GSH-Px), are considered a
promising approach to limit the extent of damage that
results from the pathogenesis of cerebrovascular diseases(6).
Griendling et al. demonstrated Ang II activated NAD(P)H
* Author for correspondence. Tel: +86-531-88382036;
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oxidases in smooth muscle cells (7). In addition, Ang II
has been shown to stimulate the activity of membranebound NAD(P)H oxidase in endothelial cells(8,9). Activated
NAD(P)H oxidase by Ang II can produce superoxide
anion (·O2-) which probably causes BMEC injury. ·O2is converted into H2O2 by the enzyme SOD. Then, H2O2
can be converted into the highly reactive hydroxyl radical
(·OH) which can be detoxified by the enzyme catalase
and GSH-Px, yielding water and oxygen. Therefore, the
activities of antioxidant enzyme are the critical protective
factor against BMEC injury. All the OFR can directly
damage the BMEC membrane and cause lipid peroxidation.
As a result, the formation of malondialdehyde (MDA),
the main decomposition product of peroxides derived
from polyunsaturated fatty acids, would be increased(10).
Therefore, we hypothesized that Ang II-induced BMEC
injury possibly through decreasing the activities of SOD and
GSH-Px, then causing serious oxidative stress in BMEC.
Ang II acts mainly via type 1 (AT1) and type 2 (AT2)
receptors. However, the effect of the AT2 receptor on Ang
II-induced BMEC injury in vitro has not been explored in
detail so far. Our second goal in this study was to identify
the role of AT1 and AT2 receptor in enhancing the oxidative
stress induced by Ang II.

Materials and Methods
I. Drugs and Reagents
Ang II, PD123319, type II collagenase, trypsin, EDTA
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were from Sigma Chemical Co. DMEM, HEPES, and
fetal bovine serum were obtained from Gibco Chemical
Co. Losartan was purchased from Merk Co. Specify antifactor VIII mouse monoclonal antibody was purchased
from Santa Cruz Biotechnology.
II. Cell Culture
Wistar rats of 2 to 3 weeks old (from Center of
Experimental Animal, Shandong University) were used
in the experiment. Cerebral microvessels were isolated
by Duan’ method(11) with modification. Cerebral cortices
cleaned of pia matters, large vessels and white matter were
rinsed with 4°C D-Hank’s solution and homogenized in
10 mL of DMEM by 20 up and down strokes in a glass
homogenizer. The homogenate was filtered through a 145
µm pore nylon sieve and rinsed with DMEM. The filtrate
containing microvessels were then filtered through a 75
µm pore nylon sieve rinsed with DMEM. The microvessel
segments were then collected, suspended in 10 mL of
DMEM, centrifuged at 150×g for 10 min, suspended in 10
mL of PBS containing 10 mg of collagenase (type II) and
10 mg of bovine serum albumin for 45 min at 37°C and
then centrifuged at 150×g for 10 min. The supernatant was
discarded and the collagenase-treated microvessels were
collected. The feeding medium was DMEM supplemented
with 20% fetal bovine serum (FBS), 1% L-glutamine,
10U·mL-1 Heparin, 100U·mL-1 penicillin, and 100µg·L-1
streptomycin. The medium was adjusted to pH 7.4 using
2.5% NaHCO 3 solution and filter-sterilized using 0.22
µm millipore filter. Next collagenase-treated microvessels
were seeded with 3 mL of feeding medium into gelatincoated flasks at densities of 10-30 pieces/cm2. Then the
primary BMEC were grown at 37°C with 5% CO2. After
5 days, the culture media were removed and fresh feeding
medium was added. Thereafter, the preparation was fed
every 3 to 4 days. In about 2 weeks, the cells appeared in
a confluent state. Cells were characterized as BMEC by
immunofluorescent staining with monoclonal antibody to
factor VIII-related antigen.
III. Experimental Design
There are 5 groups in the experiments. In the Control
group, the BMEC were incubated with normal serumdeprived DMEM (The cell viability test was performed
in serum medium.). In the Ang II group, the BMEC were
treated with 10-6 mol/L Ang II for a specified time. In the
losartan group (Los), PD 123319 group (PD) and losartan +
PD 123319 group (Los + PD), the BMEC were pretreated
with the specific AT 1 receptor antagonist losartan (10 -5
mol/L) or the specific AT2 receptor antagonist PD 123319
(10-5 mol/L) or both losartan (10-5 mol/L) and PD 123319
(10 -5 mol/L) for 30 min. Afterwards the cells were
exposed to Ang II to determine the specificity receptor
effect of Ang II.

IV. MTT Assay for Cell Viability
The MTT assay was used to measure cell viability.
The principle of this assay is that the compound
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) undergoes cellular reduction by the
mitochondrial dehydrogenase of viable cells into a blue
formazan that can be measured spectrophotometrically.
Briefly, confluent BMEC monolayers cultured in 96-well
plates were incubated with 10 -6 mol/L Ang II in the
presence and absence of 10-5 mol/L losartan or 10-5 mol/L
PD123319 for the selected periods as indicated. After the
medium was discarded, the cells were washed twice with
PBS and the medium was appended to each well. MTT (0.5
mg/mL) was added to the medium. After an additional 4 hr
of incubation, the medium was aspirated and the formazan
crystals were dissolved in 200 µL of DMSO. Cell viability
was determined to OD values at 570 nm measured by an
automatic plate reader.
V. Measurement of Lactate Dehydrogenase Release
The extent of BMEC damage was assessed by
measuring the rate of lactate dehydrogenase (LDH) release
as a marker for membrane disruption and cell death. After
48 hr, the medium and BMEC in each well were harvested
respectively for the determination of LDH by LDH
kits. Cells were removed by trypsinization, washed and
resuspended in 0.1 M phosphate buffer (pH 7.4) to a final
concentration of 107 cells/mL and then homogenized. The
homogenates were centrifuged for 30 min at 3000×g at 4°C,
and the supernatant was used.
The percentage of LDH release was deduced by the
following formula: LDH release rate (%) = extracellular
LDH contents/(extracellular LDH contents+intracellular
LDH contents) ×100%.
VI. Measurement of Lipid Peroxidation
The medium and BMEC supernatant were prepared as
described above. The content of protein in the supernatant
was determined by Bradford protein assay kit. The
resulting lipid peroxidation was evaluated by the formation
of Malondialdehyde (MDA) --the main degradation
product of peroxides derived from polyunsaturated fatty
acids. The amount of MDA was determined using the
chromogenic reagent N-methyl-2-phenylindole with
maximum absorbance at 532 nm.
VII. Measurement of Antioxidant Enzyme Activities
The supernatant prepared as described above was used
for determination of the antioxidant activity of the enzyme
superoxide dismutase (SOD) and glutathione peroxidase
(GSH-Px). The SOD activity was measured according to
the method previously reported by Flohe and Otting (12).
The reduction rate of cytochrome c by ·O2- was monitored
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Table 1. Effect of angiotensin II receptor antagonists on the relative cell viability and lactate dehydrogenase (LDH) release of rat cerebral
microvascular endothelial cells injured by angiotensin II
Group

Relative cell viability (%)

LDH release (%)

100.00 ± 1.31
71.50 ± 1.32a
91.54 ± 2.72b

10.01 ± 2.50
27.53 ± 3.97a
14.68 ± 4.82b

69.68 ± 2.65c
93.18 ± 2.40b

27.36 ± 4.66c
16.22 ± 3.92b

Control
10-6 mol·L-1 Ang II
10-6 mol·L-1 Ang II + 10-5 mol·L-1 Los
10-6 mol·L-1 Ang II +10-5 mol·L-1 PD123319
10-6 mol·L-1 Ang II + 10-5 mol·L-1 Los + 10-5 mol·L-1 PD123319
All values are mean ± S.D. (n = 6).
a
p < 0.05 vs. control group.
b
p < 0.05 vs. angiotensin II group.
c
p < 0.05 vs. losartan group.

120

Relative cell viability (%)

at 550 nm by using xantine–xantine oxidase system as
the source of ·O2-. SOD competes for ·O2- and decreases
the reduction rate of cytochrome c. The GSH-Px activity
was measured following the method described by Jaskot
et al. (13) . The supernatant was mixed with 0.1 mol/L
phosphate buffer, containing 1 nmol/L GSH, and incubated
for 5 min at 30°C. Then, the reaction had been initiated
by adding 10 µL of 7 mmol/L H 2 O 2 for 15 min, and
immediately the GSH absorbance was detected at 412 nm.
One unit of GSH-Px was defined as the amount of protein
that decreased the concentration of GSH by 1 µmol/L.

Data were presented as mean ± S.D. Groups were
compared by One-way ANOVA. Differences were
considered significant at p < 0.05.

Results
I. Determination of the Viability and LDH Release of
BMEC
As shown in Figure 1, after BMEC were exposed
to 10 -6 mol/L Ang II for 4, 8, 12, 24, 36, and 48 hr
respectively, the relative cell viability was reduced in a
time-dependent manner. Except for 4 hr, cells incubated
with 10 -6 mol/L Ang II for other times underwent
significant damaged. In order to further investigate the
extent of damage on BMEC, the LDH release was assayed
48 hr after the addition of 10-6 mol/L Ang II. We noted
that in relation to the loss of cell viability, LDH release
from BMEC also increased markedly. These effects were
blocked by AT1 specific antagonist losartan. Pretreatment
with the AT2 specific antagonist PD123319 did not alter
Ang II-induced BMEC injury significantly. Moreover,
losartan combinating with PD123319 neither diminished
nor promoted the effect of losartan alone. The above
results indicate that BMEC injury induced by Ang II
apparently mediated through AT1 receptor stimulation, but
not by AT2 receptor. Furthermore, the protective effect of
the AT1 specific antagonist losartan may not be directly
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Figure 1. Time course of relative cell viability of rat brain
microvascular endothelial cells exposed to angiotensin II. Data
are mean ± S.D. of 9 independent experiments that used separate
endothelial cell isolates. ap < 0.05 vs. control group.

related to Ang II activating unblocked AT 2 receptor in
vitro. (Figure 1, Table 1).
II. Determination of Lipid Peroxidation
Our results demonstrated that the BMEC group
treated with Ang II increased MDA, compared with
untreated control group which indicated that extensive
lipid peroxidation had taken place in these damaged
cells. Pretreatment with the AT 1 antagonist losartan
alone suppressed the formation of MDA exerted by Ang
II significantly; while pretreatment with AT2 antagonist
PD123319 alone exhibited no influence on the formation
of MDA induced by Ang II. However there was no
significant difference in MDA formation between losartan
group and losartan + PD123319 group (Table 2).
III. Determination of Intracellular Antioxidant Enzyme
Activities
The level of activity of the antioxidative enzymes, SOD
and GSH-Px was also determined. As shown in Figure 2,
10-6 mol/L Ang II treatment markedly reduced the level of
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Table 2. Effect of angiotensin II receptor antagonists on angiotensin II-induced lipid peroxidation in the medium and rat cerebral microvascular
endothelial cells
MDA in medium (nmol/ml)

MDA in cells (nmol/mg protein)

Control
10-6 mol·L-1 Ang II

Group

0.75 ± 0.058
4.64 ± 0.60a

5.17 ± 1.00
28.53 ± 2.01a

10-6 mol·L-1 Ang II + 10-5 mol·L--1 Los

2.02 ± 0.29b

13.44 ± 1.31b

10-6 mol·L-1 Ang II + 10-5 mol·L-1 PD123319
10-6 mol·L-1 Ang II + 10-5 mol·L-1 Los + 10-5 mol·L-1 PD123319

5.04 ± 0.44c
2.16 ± 0.45b

29.03 ± 1.99c
13.75 ± 1.11b

activity of SOD and GSH-Px in BMEC by 52% and 42%,
respectively. Pretreatment with the AT1 specific antagonist
losartan (10-5 mol/L) produced an evident recovery; whereas
PD123319 pretreatment did not alter the reduction of
SOD and GSH-Px activity in BMEC induced by Ang II.
Moreover, no significant change in the level of activity for
these enzymes was detected in the additional presence of
PD123319 compared with pretreatment with losartan alone.

Antioxidant enzyme activity
(U/mg protein)

Each value represents the mean ± S.D. of six experiments.
a
p < 0.05 vs. control group.
b
p < 0.05 vs. Ang II group.
c
p < 0.05 vs. losartan group.
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Discussion
An increasing number of studies suggest that Ang II is
involved in the pathology of cerebrovascular disease partly
by injuring BMEC(2, 3, 4, 14), but the mechanisms involved
are not elucidated. In the present study, the relative cell
viability and the LDH release were used to evaluate the
extent of BMEC injury. In agreement with previous
reports, our result showed that 10-6 mol/L Ang II increased
LDH leakage and time-dependently inhibited the viability
of BMEC.
Ang II has been shown to stimulate the activity of
membrane-bound NAD(P)H oxidase in endothelial cells
which participates in endothelial dysfunction(8,9), but not in
BMEC. OFR are likely participants in the pathogenesis of
cerebrovascular diseases and can significantly increase lipid
peroxidation in BMEC, which was evaluated by measuring
MDA content in the experiment(10). It is becoming clear that
oxidative stress induces an adaptive antioxidant response
within the cell and the level of antioxidant enzymes appears
to be lower(15). In addition to observing lipid peroxidation,
we also examined activity of the antioxidant enzymes
including SOD and GSH-Px to identify the oxidative
stress in BMEC. The results showed that Ang II treatment
increased the intracellular and extracellular medium MDA
content and decreased the level of activity of intracellular
SOD and GSH-Px in BMEC, compared to an untreated
control group. These findings indicate that Ang II causes
injury to BMEC by increasing free radicals and decreasing
endogenous antioxidant defense. They further suggest that
oxidative stress induced by Ang II plays an important role in
causing or mediating BMEC injury.
Ang II is known to act mainly through the AT1 and

Figure 2. Effect of angiotensin II receptor antagonists on the
activities of superoxide dismutase and glutathione peroxidase in
angiotensin II-treated rat cerebral microvascular endothelial cells.
Cells were pooled and homogenized after being incubated for
48 hr with 10-6 mol/L angiotensin II in the presence or absence of
10 -5 mol/L losartan (Los) or 10 -5 mol/L PD123319 (PD). The
homogenate was centrifuged and the activities of intracellular
antioxidant enzymes in the supernatant were determined. Each value
represents the mean ± S.D. of six experiments. #p < 0.05 vs. control
group, *p < 0.05 vs. angiotensin II group, ∆p < 0.05 vs. losartan
group.

AT2 receptors. The AT1 receptor-mediate Ang II actions
are best defined in the brain. Longterm treatment with
AT1 receptors antagonists has been reported to improve
the neurological outcome and reduce the infarct volume
after experimental focal brain ischemia in stroke-prone
hypertensive rats before the reduction in blood pressure(16).
Walter et al. also reported that a smaller lesion area
was observed after MCA occlusion in AT 1 receptordeficient mice (17) . It also has been reported that AT 1
receptor antagonist prevents brain edema by inhibiting
cerebrovascular endothelial cell injury induced by Ang
II without lowering blood pressure (14) . However, the
function of AT2 receptors is less well defined; they may
counterbalance the effects of AT 1 receptor stimulation
in most tissues. Some authors have speculated that
when the AT 1 receptor is blocked by an AT 1 receptor
antagonist, unbound Ang II acts preferentially on the
AT 2 receptor, which may contribute to the beneficial
action of AT 1 receptor antagonist (18-20). Iwai et al. (21)
reported that significantly larger ischemic area and greater
neurological deficit were observed after MCA occlusion
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in AT 2 receptor-deficient mice than in wild-type mice.
Therefore, the effect of the stimulation of the AT2 receptor
is becoming increasingly important in both physiological
and pathological situations.
In this study we investigated the contribution of
the AT 2 receptors in Ang II-induced BMEC injury. We
speculated that AT 2 receptors may act to oppose the
AT 1 -receptor mediated effect in BMEC. Therefore,
the PD 123319 (selective block AT 2 receptor) group
and the losartan + PD 123319 (block both AT1 and AT2
receptor) group were designed to investigate the role of
AT 2 receptor in BMEC injury induced by Ang II. Our
results demonstrated that pretreatment with the AT 1
selective blocker losartan significantly prevented Ang IIinduced BMEC injury, reduced the MDA formation and
increased the activity of SOD and GSH-Px. In contrast,
the selective blocking of the AT2 receptor with PD123319
did not markedly bring about these effects. There was no
significant difference, in this regard, between the losartan
and losartan + PD 123319 groups. Taken together, it
appears that BMEC injury and the oxidative stress induced
by Ang II seem to involve AT 1 more than AT 2 receptor.
This result contrasts with the report(21) that AT2 receptor
stimulation has a protective effect on ischemic brain
lesions in mouse focal brain ischemia induced by MCAO,
at least partly through the modulation of cerebral blood
flow and superoxide production. The reason is perhaps
that the conditions (physiological) in BMEC in vitro differ
from those in brain ischemia model (pathological) in vivo.
In conclusion, the present study demonstrates that Ang
II injury of the BMEC possibly occurs through induction of
oxidative stress by activating AT1 receptors, which is then
involved in the development of cerebrovascular disease.
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